AMD3100 is the only marketed CXCL12/CXCR4 antagonist and was approved by the FDA in 2008 for autologous transplantation in patients with non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM). Here, CXCR4 is linked to non-Hodgkin lymphoma.